Search clinical trials for: GalNAc

Total 5 results

Sirnaomics

Recruiting

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

FXI

United States, Canada
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Enrolling by invitation

Long Term Extension Study in Patients With Primary Hyperoxaluria (PHYOX3)

Kidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2) | Primary Hyperoxaluria Type 3 (PH3)

United States, France, Germany, Japan, Lebanon, Spain, United Kingdom, Australia, Canada, Italy, Netherlands, Norway, Turkey
Dicerna Pharmaceuticals, Inc.

Completed

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 (PHYOX2)

Kidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2)

Poland, United Kingdom, New Zealand, United States, Australia, Canada, France, Germany, Israel, Italy, Japan, Lebanon, Netherlands, Romania, Spain
Dicerna Pharmaceuticals, Inc.

Completed

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients (PHYOX4)

Primary Hyperoxaluria Type 3

United States, Germany, Netherlands, United Kingdom
Silence Therapeutics plc

Withdrawn

Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

Non-transfusion-dependent Thalassemia | Low Risk Myelodysplastic Syndrome

United Kingdom, Bulgaria

3

Subscribe